A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) Has a type of cancer called colorectal adenocarcinoma that has spread to other parts of the body or is in a spot where surgery is not an option
    2. 2) Availability of tumor tissue for a biopsy
    3. 3) Hasn't had any treatment for their colorectal cancer that has spread to other parts of the body, except for the first round of treatment they received when they were first diagnosed

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Confirmed if the tumor has MSI-H (high microsatellite instability) by using a method called immunohistochemistry (IHC) either at a local lab or a central lab or by using a method called polymerase chain reaction (PCR)
    2. 2) Your disease can be surgically removed, as determined by the researcher, either during or after initial treatment
    3. 3) Treatment given at the beginning of the patient's care, known as the induction treatment, started within 6 months of finishing any previous chemotherapy or if radiation therapy was given before the main treatment



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.